%0 Journal Article
%T Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes
%A Bin Zhou
%A Jie Li
%A Naichao Liang
%A Tao Wang
%A Yang Liu
%A Yundong Zhang
%A Zhi Wang
%A Zhouhuan Dong
%J Archive of "OncoTargets and therapy".
%D 2016
%R 10.2147/OTT.S93823
%X Epidermal growth factor receptor¨Ctyrosine kinase inhibitors (EGFR¨CTKIs) have demonstrated efficacy in treating advanced non-small-cell lung cancer (NSCLC). Preliminary findings suggested that EGFR¨CTKIs might also be beneficial in neoadjuvant therapy in treating NSCLC. Therefore, this study aimed to evaluate the efficacy and safety of neoadjuvant therapy with icotinib in patients with early-stage NSCLC
%K non-small-cell lung cancer
%K epidermal growth factor receptor
%K tyrosine kinase inhibitor
%K neoadjuvant
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809345/